Sangamo Therapeutics Inc (SGMO) Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 30.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 326,275 shares of the biopharmaceutical company’s stock after selling 142,824 shares during the period. American Century Companies Inc. owned 0.37% of Sangamo Therapeutics worth $6,199,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of SGMO. Schwab Charles Investment Management Inc. lifted its stake in shares of Sangamo Therapeutics by 13.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 433,717 shares of the biopharmaceutical company’s stock worth $7,113,000 after acquiring an additional 51,801 shares during the period. Chicago Equity Partners LLC acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $192,000. Teacher Retirement System of Texas acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $443,000. California Public Employees Retirement System lifted its stake in shares of Sangamo Therapeutics by 30.6% in the 4th quarter. California Public Employees Retirement System now owns 149,235 shares of the biopharmaceutical company’s stock worth $2,447,000 after acquiring an additional 34,935 shares during the period. Finally, Swiss National Bank lifted its stake in Sangamo Therapeutics by 3.9% during the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock valued at $2,336,000 after purchasing an additional 5,400 shares during the last quarter. 56.37% of the stock is owned by institutional investors.

In other news, Director Steven J. Mento sold 9,433 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $23.27, for a total transaction of $219,505.91. Following the sale, the director now owns 8,480 shares in the company, valued at $197,329.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven J. Mento sold 7,215 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $18.40, for a total transaction of $132,756.00. The disclosure for this sale can be found here. Insiders have sold 81,539 shares of company stock worth $1,734,825 in the last 90 days. 1.20% of the stock is owned by company insiders.

SGMO stock opened at $16.00 on Thursday. Sangamo Therapeutics Inc has a 12 month low of $6.55 and a 12 month high of $27.50. The company has a market cap of $1.57 billion, a P/E ratio of -22.86 and a beta of 2.83. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 0.14.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. The business had revenue of $12.60 million for the quarter, compared to analyst estimates of $53.09 million. During the same period in the prior year, the company earned ($0.23) earnings per share. The firm’s revenue for the quarter was up 270.6% on a year-over-year basis. equities analysts predict that Sangamo Therapeutics Inc will post -0.54 earnings per share for the current fiscal year.

SGMO has been the subject of several recent research reports. ValuEngine lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 8th. Barclays reissued a “buy” rating and set a $30.00 target price on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Jefferies Group reissued a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 24th. Finally, Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Tuesday, May 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $21.67.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply